Professor of Medicine
Atrium Health
Charlotte, NC, United States
Baharak Moshiree, MD, MSc, FACG, is a Professor of Medicine and Director of Motility in the Division of Gastroenterology at the University of North Carolina, Atrium Health, in Charlotte, NC. She trained at the University of Florida for a combined undergraduate and medical school, later gastroenterology fellowship with a focus on functional bowel diseases and motility disorders. She has a master’s degree in clinical investigation and was on a National Institutes of Health (NIH) T32 grant. Her expertise and interests are in the diagnosis and management of patients with chronic gastrointestinal illnesses such as gastroparesis, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), and constipation with pelvic floor disorders. Dr. Moshiree's earlier research focused on the multidimensional pathophysiology of IBS and examining pain processing mechanisms and brain-gut interactions in patients with IBS and functional dyspepsia. She has also participated in several multinational studies in both IBS and gastroparesis. Dr. Moshiree has continuous funding from the Cystic Fibrosis Foundation (CFF), targeting better treatment options for patients with CF, and recently helped publish CF guidelines for treatment of GERD in patients with chronic lung disease. She is also one of three Principal Investigators in a national study to examine the prevalence of GI symptoms in patients with CF called GALAXY, funded by the CF foundation. Dr. Moshiree has presented her research at several national meetings and has received the Preceptor of the Year Award/Academician of Year from Atrium Health 2020. Dr. Moshiree is currently on the AGA’s Institute Council (2017-present) and a Council Member of the American Neurogastroenterology and Motility Society. She currently serves as the ACG Governor for North Carolina. She recently was a co-author on the ACG's IBS Guidelines and is excited to serve as Associate Editor for the American Journal of Gastroenterology.
Allergan (Individual(s) Involved: Self): Advisory Committee/Board Member; Alnylam Pharma (Individual(s) Involved: Self): Consultant, Grant/Research Support; Bausch Pharmaceuticals (Individual(s) Involved: Self): Consultant; Cairn Diagnostics (Individual(s) Involved: Self): Advisory Committee/Board Member; Cystic Fibrosis Foundation (Individual(s) Involved: Self): Grant/Research Support; GI Health Foundation (Individual(s) Involved: Self): Speaker's Bureau; GI Pill (Individual(s) Involved: Self): Intellectual Property / Patents; Medtronic (Individual(s) Involved: Self): Grant/Research Support, Speaker's Bureau; Progenity (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support; Salix (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support; Synergy (Individual(s) Involved: Self): Consultant; Takeda (Individual(s) Involved: Self): Advisory Committee/Board Member, Grant/Research Support; Urovant (Individual(s) Involved: Self): Grant/Research Support